Hanspeter Gerber
Chief Scientific Officer Sutro Biopharma
Dr. Hans-Peter Gerber brings 30 years of R&D experience in oncology drug development, specializing in ADCs, redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built successful drug development teams across pharma, biotech, and startups, overseeing preclinical development with low clinical attrition rates. Notably, he has contributed to the development of 6 of the 15 approved ADCs.
In September 2023, Hans-Peter joined Sutro Biopharma as CSO, leading a research team of 80 FTEs. He co-founded Codeable Therapeutics in 2022, focusing on next-generation ADCs that induce immunogenic cell death, and successfully secured seed funding in 2023.
Seminars
Tuesday 13th October 2026
Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance
9:30 am
- Laying out the development and vision of STRO-004 leveraging enhanced antibody engineering and linker-payload design to translate into impactful clinical performance against existing ADC therapies
- Exploring brand-new Phase I clinical safety and PK data targeting Tissue Factor, contextualized with how well STRO-004 translated from cyno monkey preclinical data, to understand ADC clinical benefit and enhanced therapeutic index
- Highlighting rationale, development and the power of dual payload ADCs to subvert patient resistance mechanisms to single payload ADCs
